Search the Site


test tubes

$EXAS Cologuard Pivotal Study Underway as Product Development Continues

publication date: Sep 27, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
EXACT Sciences (NASDAQ:EXAS) is a molecular diagnostics company focused on the late-stage development of a new non-invasive, genetic (DNA) based screening test designed to improve the rate of early detection of colorectal cancer (CRC).

Sorry this page is available to subscribers only. 

You can also sign up for our 100% FREE Newsletter  to stay current on public webinars, special offers, and news alerts:


If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.